Sanofi (SNY) EBITDA (2009 - 2026)

Sanofi (SNY) has 18 years of EBITDA data on file, last reported at $14.4 billion in Q1 2026.

• Quarterly EBITDA rose 15.5% year-over-year to $14.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.3 billion (up 33.65% YoY) and the FY2025 annual result came in at $7.4 billion, down 4.71% from the prior year.
• EBITDA climbed to $14.4 billion in Q1 2026 per SNY's latest filing, from $13.4 billion in the prior quarter.
• The five-year high for EBITDA was $52.4 billion in Q4 2023, with the low at $12.1 billion in Q1 2024.
• Average EBITDA over 5 years is $18.5 billion, with a median of $13.9 billion recorded in 2025.
• Year-over-year, EBITDA sank 52.39% in 2024 and surged 201.14% in 2025.
• Sanofi's EBITDA stood at $17.8 billion in 2022, then jumped by 193.46% to $52.4 billion in 2023, then slumped by 52.39% to $24.9 billion in 2024, then slumped by 46.26% to $13.4 billion in 2025, then climbed by 7.45% to $14.4 billion in 2026.
• Business Quant data shows SNY's EBITDA at $14.4 billion in Q1 2026, $13.4 billion in Q4 2025, and $44.6 billion in Q3 2025.